Schering Claritin TV ads revised Aug. 22 following FDA notice of violation letter.
This article was originally published in The Tan Sheet
Executive Summary
SCHERING CLARITIN DTC ADS REVISED, CLEARED BY FDA AUG. 22 for broadcast following the company's receipt of an Aug. 19 agency notice of violation letter for ads for the prescription nonsedating antihistamine. Two 30-second Claritin TV ads debuted Aug. 15 under the aegis of the agency's Aug. 8 voluntary guidance on direct-to-consumer advertising that allows companies to use both the brand name of an Rx drug and efficacy data but also requires a "major statement" about risk factors ("The Tan Sheet" Aug. 18, p. 4).